[go: up one dir, main page]

WO2012030309A3 - Formulation of comprising tiotropium and a calcium channel blocker - Google Patents

Formulation of comprising tiotropium and a calcium channel blocker Download PDF

Info

Publication number
WO2012030309A3
WO2012030309A3 PCT/TR2011/000199 TR2011000199W WO2012030309A3 WO 2012030309 A3 WO2012030309 A3 WO 2012030309A3 TR 2011000199 W TR2011000199 W TR 2011000199W WO 2012030309 A3 WO2012030309 A3 WO 2012030309A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
calcium channel
channel blocker
formulation
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000199
Other languages
French (fr)
Other versions
WO2012030309A2 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP11767092.7A priority Critical patent/EP2611447A2/en
Publication of WO2012030309A2 publication Critical patent/WO2012030309A2/en
Publication of WO2012030309A3 publication Critical patent/WO2012030309A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a dry powder formulation comprising at least one calcium channel blocker and tiotropium developed in order to be used in respiratory tract diseases such as asthma and COPD.
PCT/TR2011/000199 2010-09-01 2011-08-24 Formulation of calcium channel blocker Ceased WO2012030309A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11767092.7A EP2611447A2 (en) 2010-09-01 2011-08-24 Formulation of comprising tiotropium and a calcium channel blocker

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07251 2010-09-01
TR2010/07251A TR201007251A2 (en) 2010-09-01 2010-09-01 Calcium channel blocker formulation.

Publications (2)

Publication Number Publication Date
WO2012030309A2 WO2012030309A2 (en) 2012-03-08
WO2012030309A3 true WO2012030309A3 (en) 2012-08-09

Family

ID=44764205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000199 Ceased WO2012030309A2 (en) 2010-09-01 2011-08-24 Formulation of calcium channel blocker

Country Status (3)

Country Link
EP (1) EP2611447A2 (en)
TR (1) TR201007251A2 (en)
WO (1) WO2012030309A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543470T3 (en) * 2009-09-30 2015-08-19 Microdose Therapeutx, Inc. Methods and compositions for the treatment of Raynaud's phenomenon
JP6092015B2 (en) * 2013-06-19 2017-03-08 日本碍子株式会社 Method for producing single crystal

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004691B1 (en) * 1985-07-02 1989-11-25 키 파마슈티칼스, 인코포레이티드 Treatment and composition for chronic obstructive pulmonary disease
US20020106332A1 (en) * 2000-10-12 2002-08-08 Michael Walz Process for preparing powder formulations
US20020110529A1 (en) * 2000-10-12 2002-08-15 Karoline Bechtold-Peters Inhalable powder containing tiotropium
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003088944A1 (en) * 2002-04-13 2003-10-30 Glaxo Group Limited Dry powder inhalant composition
WO2008152398A2 (en) * 2007-06-14 2008-12-18 Cipla Limited Formulations for inhalation
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261161A1 (en) 2000-05-30 2001-12-11 Ortho-Mcneil Pharmaceutical, Inc. Dihydropyridine compounds for inhibition of calcium-influx

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004691B1 (en) * 1985-07-02 1989-11-25 키 파마슈티칼스, 인코포레이티드 Treatment and composition for chronic obstructive pulmonary disease
US20020106332A1 (en) * 2000-10-12 2002-08-08 Michael Walz Process for preparing powder formulations
US20020110529A1 (en) * 2000-10-12 2002-08-15 Karoline Bechtold-Peters Inhalable powder containing tiotropium
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2003088944A1 (en) * 2002-04-13 2003-10-30 Glaxo Group Limited Dry powder inhalant composition
WO2008152398A2 (en) * 2007-06-14 2008-12-18 Cipla Limited Formulations for inhalation

Also Published As

Publication number Publication date
EP2611447A2 (en) 2013-07-10
WO2012030309A2 (en) 2012-03-08
TR201007251A2 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
EP2502644B8 (en) Dose counters for inhalers, inhalers and shafts thereof
WO2011131943A8 (en) Pharmaceutical compositions
IL221133A (en) Process, tube and device for the preparation of wound healant composition
WO2011152804A3 (en) Process for dry powder formulations
ZA201503554B (en) Compositions for balancing gut microbiota and the preparation and the uses thereof
ZA201209475B (en) Compositions comprising a near terminal-branched compound and methods of making the same
IL222268A (en) Substituted pyrrolo-pyridines, pharmaceutical compositions comprising them, combined compositions comprising them and their use in the manufacture of medicaments
IL226448A (en) Immunogenic composition comprising an m72 related antigen and uses thereof in the manufacture of a medicament
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
EP3013348A4 (en) A medicinal composition of amaranth extract origin having enriched nitrate content and a method of preparing the same
WO2010094731A3 (en) Pharmaceutical composition for inhalation
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
IL222723A0 (en) Respiratory syncytial virus antigenic compositions and methods
EP2370068A4 (en) Methods and compositions for delivery of medicaments to the lungs
ZA201500208B (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
SG10201502583VA (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
EP2560626A4 (en) Local anesthetic emulsion compositions and methods of making and using the same
EP2995614B8 (en) Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
EP2542059A4 (en) Compositions comprising myristic acid and uses thereof
IL226174A0 (en) Propellant compositions and methods of making and using the same
WO2012030309A3 (en) Formulation of comprising tiotropium and a calcium channel blocker
WO2012030308A3 (en) Formulation comprising cellobiose
EP2866792A4 (en) Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture
ZA201105443B (en) Novel saponin compounds,methods of preparation thereof,use thereof and pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11767092

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011767092

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE